Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From the Netherlands and the United Kingdom

In this episode, Thomas Powles, MBBS, MRCP, MD, and Michiel van der Heijden, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United Kingdom and the Netherlands. Topics include:

• Data from registrational trials in the European Union for pembrolizumab and atezolizumab in the first-line/second-line settings
• Utility of PD-L1 and tumor mutational burden as biomarkers for immune checkpoint inhibitor–based therapy
• Results from the JAVELIN trial on avelumab maintenance after chemotherapy
• When to consider first-line treatment with immune checkpoint inhibitor–based therapy vs chemotherapy

Presenters:

Thomas Powles, MBBS, MRCP, MD
Deputy Centre Lead
Centre for Experimental Cancer Medicine
Barts Cancer Institute
Queen Mary University of London
Professor of Urology Cancer
Director of Barts Cancer Centre
Department of Cancer
St Bartholomew's Hospital (Barts Health NHS Trust)
London, United Kingdom

Michiel van der Heijden, MD, PhD
Medical Oncologist and Research Group Leader
Department of Medical Oncology and Molecular Carcinogenesis
Stichting Het Nederlands Kanker Instituut – Antoni van Leeuwenhoek Ziekenhuis
Medical Oncologist 
Antoni van Leeuwenhoek Ziekenhuis/Netherlands Cancer Institute
Amsterdam, the Netherlands

Content based on an online IME program supported by educational grants from Pfizer and EMD Serono, Inc.

Link to full program, including associated downloadable slidesets and on-demand Webcast:
https://bit.ly/3kJC5SL

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.